Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial

NCT04375098 is registered in ClinicalTrials.gov with Pontificia Universidad Catolica de Chile as lead sponsor.

NCT NCT04375098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial
Lead sponsor
Pontificia Universidad Catolica de Chile
Phase
Phase 2
Overall status
Completed
Start date
May 4, 2020
Completion date
August 17, 2020
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe acute respiratory syndrome coronavirus 2